- Journalists Talk Hot Health Topics: Urgent Care Clinics Performing Abortions and Doulas’ Pay
- ASCs’ vendor problem
- Providence’s physician chief on its ‘holistic’ approach to value-based care
- What the Health? From KFF Health News: A New CDC Nominee, Again
- States Update Guardianship Laws To Keep Children of Immigrants Out of Foster Care
- Anesthesia job market faces ‘major disruption’
- Florida system raises $100M for new ED
- North Carolina system names COO
- Mark Cuban wants to bring drug manufacturing to hospitals’ doorsteps — literally
- UCI Health names chief AI officer
- Nevada hospital names CEO
- Saint Luke’s taps president for 2 hospitals
- Dental community mourns dentist killed in murder-suicide
- Mass General Brigham, CVS deal could raise healthcare spending $40M annually: Report
- Ideal Dental opens 1st Oklahoma practice, expands in 2 more states
- PDS Health eyes the next era of medical-dental integration
- Mark Cuban dives into direct contracting
- HCA executive pay by the numbers
- Iris Telehealth offers behavioral health analytics platform
- HHS names chief economist, regulatory leader to address healthcare affordability
- Loma Linda University Health names new president
- The best ASCs for colonoscopy, endoscopy in the South: US News
- Tennessee moves forward with CON repeal
- Dental schools take action to alleviate workforce shortages: 6 updates
- American Medical Group Association partners with Talkiatry to expand psych access
- Trump nominates CDC director
- ChristianaCare, Cardiovascular Physicians of Delaware to open joint venture ASC
- 5 states regulating AI in mental health
- Centerstone debuts $13M youth behavioral health campus in Missouri
- 3 DSOs making headlines
- Maine restricts noncompetes for rural healthcare workers
- Heartland Dental opens Florida office
- The 10 biggest ASC deals of the last 5 years
- Affordability, transparency: A look at large employers' top healthcare concerns
- 10 dental Medicaid updates to know from Q1
- White House eyes ibogaine research expansion
- New Weight Loss Research Questions Need for GLP-1 Drugs
- Trump Names CDC Director Pick
- SocialRx teams up with FQHC in NYC to prescribe arts and culture for chronically ill patients
- FDA To Review Whether To Allow More Access To Certain Peptides
- Rising Colon Cancer Deaths Hit Younger Adults Without Degrees Hardest
- The Healthccare Burnout Backlask (pt 4): Why Contract Negotiation Has Become a Core Strategic Skill for Healthcare Administrators
- The Healthccare Burnout Backlask (pt 4): Why Contract Negotiation Has Become a Core Strategic Skill for Healthcare Administrators
- Over 80% of PCPs concerned about financial stability over next several years
- Industry Voices—DOJ jumps into 340B cases over state law, raising questions about federal plans for the program
- FDA's accelerated approval pathway needs stronger transparency, evidence standards: ICER
- Most People Would Take A Blood Test For Alzheimer's, Study Says
- This Sexually Transmitted Infection Linked To Heart Attack, Stroke
- How Playtime at Age 2, Especially with Parents, Shapes Teen Fitness Habits
- New Depression Treatment Matches ECT with Less Memory Loss, Study Says
- Memory Problems? Your Salt Intake Could Make Matters Worse, Study Says
- Ultra-Processed Foods Linked To Fatty Muscles, Potential Knee Arthritis
- Your New Therapist: Chatty, Leaky, and Hardly Human
- Teva scores in appeal as court revives $177M verdict against Lilly in migraine patent spat
- Gen AI chatbots continually struggle with differential diagnoses, Mass General Brigham study finds
- Listen: With Little Federal Regulation, States Are Left To Shape the Rules on AI in Health Care
- Fierce Pharma Asia—Astellas’ stem cell therapy rethink; GSK’s bullish ADC plan; Daiichi’s OTC sale
- BIO comes out swinging with 'Fight of Our Lives' campaign for the industry’s 50th birthday
- The future of medical-dental integration is here
- Texas dentist has license suspended
- Efforts grow to limit corporate dental ownership, protect dentist autonomy: 6 updates
- What’s the deal with insurer mental health parity violations?
- Remarks at the Options Market Structure Roundtable
- Wider care gaps predicted as mental health parity rule faces rollback
- Sheppard Pratt gets $16.5M for behavioral health expansion
- Former Deputy Surgeon General Erica Schwartz, M.D., nominated as CDC director
- Verily Health simplifies medical jargon alphabet soup with AI-powered app in new campaign
- 10 trends in behavioral health usage: Report
- Cattywampus: Statement on the CAT Concept Release
- Providers' advantage on out-of-network billing disputes likely to continue: Capstone
- Butterflies and Condors: Remarks at the Options Market Roundtable
- Viatris, Teva kick off separate recalls over dissolution, raw material issues
- Mental health ED visits at Children’s Hospital Colorado jump 20% in April
- Rising ACA Costs Leave Many Unable To Pay for Coverage
- One Lot of Xanax Recalled Nationwide Over Quality Issue, FDA Says
- Cough Drops From Several Brands Being Recalled, FDA Says
- CDC May Get New Leader as Officials Consider Erica Schwartz
- Statement at the Roundtable on Options
- Opening Remarks at the Options Market Structure Roundtable
- APA launches resource library for trusted digital mental health tools
- E-Bikes And E-Scooters A Growing Menace On City Streets, Study Says
- 'Absent or trivial' effects: Anti-amyloid Alzheimer's drugs called into question once again
- RFK Jr. kicks off string of congressional hearings to talk White House budget plan
- This Simple Step Could Improve The Benefits From Your Regular Workouts
- New Alzheimer's Drugs Provide No Meaningful Benefit, Major Evidence Review Concludes
- Air Pollution and Weather Tied to Migraines
- Study Says Stress, Weight And Hormones Alter Timing of Puberty in Girls
- Why Walking Remains Unsteady After Partial Spinal Cord Injury
- Roche to launch another Elevidys study after EU rejection of Duchenne gene therapy
- Lilly answers FDA's call for more Foundayo safety info, plotting diabetes filing in parallel
- New Federal Medicaid Rules Require One Month of Work. Some States Demand More.
- As US Birth Rate Falls, Feds’ Response May Make Pregnancy More Dangerous
- Omnicom brews Olixir from FCB Health, rebranding storied agency after Interpublic takeover
- DiMe-led initiative brings together pharma, virtual providers, digital pharmacies to develop blueprint for DTC pharma models
- UPDATED: Heeding RFK Jr.'s call, FDA reclassifies 12 unapproved peptides ahead of advisory committee meeting
- Carrot launches proprietary AI platform for personalized fertility, family care
- UC Health workers plan open-ended, system-wide strike for May 14
- Baylor Scott & White Health Plan to depart individual market, Medicaid this year
- In industry's latest OTC pivot, Daiichi Sankyo lines up $1.5B consumer health unit sale to beverage giant Suntory
- EPA Delays Decisions on 'Forever Chemicals'
- Wildlife Trade Tied To Higher Risk of Diseases Spreading to Humans
- Yes, This is the Worst Pollen Season Ever — Until Next Year
- GoodRx launches 7.2-mg Wegovy dose for self-pay patients at $399 per month
- Providers back bipartisan bill eliminating Medicare chronic care management cost sharing
- Progyny unveils new fertility benefit option for small, mid-size employers
- New Weight Loss Pill, Foundayo, Gets Approval But FDA Seeks More Safety Data
- Seqster launches new data tool to turn clinical sites into 'research-ready data collection points'
- Gilead widens global Yeztugo access agreement, but MSF says supply is 'not nearly enough'
- Novartis CEO Vas Narasimhan joins Anthropic’s board as biopharma’s ties to AI deepen
- Behavioral health utilization is up with anxiety disorders leading demand, report finds
- Does Your Child Have A Concussion? These Are The Signs, Review Says
- AI Reveals Negative Labels in Medical Records for Sickle Cell Patients
- 'Food-as-Medicine' Improves Life for Heart Failure Patients
- Silent Heart Rhythm Problem Might Triple Risk Of Heart Failure In Seniors
- Blood Test Predicts Alzheimer's Years Before Symptoms, Brain Changes
- An Infectious Combo Triples Risk Of MS, Study Says
- Astellas manufacturing chief views reliable supply, bridging research as his production 'north star'
- Physician compensation up 3% in 2025, but not all specialties saw raises: Medscape
- Pfizer recruits former Angel Lucy Liu for latest mission against cancer
- Teva launches new online schizophrenia community project
- One man’s journey from gambling addiction to recovery and advocacy
- Rural Nebraska Dialysis Unit Closes Despite the State’s $219M in Rural Health Funding
- Medi-Cal Immigrant Enrollment Is Dropping. Researchers Point to Trump’s Policies.
- Ionis exec shares method to the Madness after 2026 Drug Name Tournament win
- Abridge expands clinical decision support solution with UpToDate partnership, new NEJM, JAMA content tie-ups
- Travere maps course for Filspari's $3B US opportunity after landmark rare disease nod
- Hospitals with more disadvantaged patients fall short on price transparency, study finds
- FDA tells Eli Lilly to round up more safety info on key obesity launch Foundayo
- Meat Consumption Rises as Protein Trend Grows, Experts Warn
- Bill would force payers to apply DTC drug purchases to patient deductibles
- Nuts.com Recalls 10,000+ Pounds of Candy Over Allergy Risk
- Listen to the Latest ‘KFF Health News Minute’
- Keebler Health secures $16M in series A funding for AI-powered risk adjustment platform
- Sam’s Club Recalls Children’s Pajamas Due to Fire Hazard
- Small Talk? It May Be Better Than You Think
- J&J, chasing $100B year, sports immunology ‘dual powerhouse’ of Tremfya and new launch Icotyde
- Long-Term Opioid Prescriptions Fall By About A Quarter
- Gut Bacteria Might Drive Rare Food Allergy in Children, Study Finds
- Stents Can Ease Long-Term Symptoms Of Deep Vein Thrombosis, Trial Shows
- Young Cancer Survivors Face Doubled Risk Of Subsequent New Cancer
- Does Your Child Have Nightmares? Here's One Solution
- Marriage's Hidden Benefit? A Lower Risk Of Cancer
- Novo taps OpenAI to deploy AI across R&D, manufacturing and corporate functions
- Pfizer rebuked by FDA for misleading Adcetris ads on Facebook
- FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results
- FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results
- Freedom of Associations
- Interfacing with our Inner Demons: Comments on the Division of Trading and Markets' Statement on Certain User Interfaces
- Staff Statement Regarding Broker-Dealer Registration of Certain User Interfaces Utilized to Prepare Transactions in Crypto Asset Securities
- Statement Regarding Staff No-Action Letter to Bank of England
The Trump Administration is developing a web site named TrumpRx.com. Only a lander is up right now at that URL, but the web site will eventually direct Americans to sources for pharmaceuticals whose prices have been lowered by Most Favored Nation (MFN) agreements:
https://thehill.com/homenews/5529456-trumprx-online-platform-drugs/
White House launching TrumpRx.com for lower-priced drugs: What to know
By Joseph Choi - September 30, 2025The Trump administration on Tuesday announced plans to launch TrumpRx.com, an online platform that it says will direct Americans to lower-priced drugs.
The announcement came one day after President Trump’s deadline for drugmakers to comply with his “Most Favored Nation” (MFN) executive order, which included a mandate for companies to establish direct-to-consumer for medicines, cutting out middlemen.
Chris Klomp, deputy administrator of the Centers for Medicare and Medicaid Services, said on Tuesday that drugs would be made available through the platform “often at full MFN, and always at lower prices than currently available. This is bypassing middlemen. It increases transparency, and many instances, prices are 80 percent lower than they are today.”
A senior administration official said it hoped to launch the website early next year, in a briefing Tuesday.
“To be clear, the government is not getting into the drug distribution business. Rather, this is a convening site where Americans can come and know that this is a place where they can go direct-to-consumer and access the lowest prices available through the President’s MFN initiative,” they added.
How the site will be constructed and other finer details are still being worked out, according to the official.
Asked whether patients will be able to use their insurance to purchase drugs through TrumpRx.com, a senior administration official did not directly answer, noting instead that pharmaceutical manufacturers are often public companies with fiduciary responsibilities to their shareholders as well as other “obscures priorities.”
The move echoes on that the pharmaceutical industry launched just the day before, with the trade group PhRMA launching AmericasMedicines.com on Monday, gathering different drugmakers that currently offer direct-to-consumer programs.
TrumpRx.gov is now up and running:
Fact Sheet: President Donald J. Trump Launches TrumpRx.gov to Bring Lower Drug Prices to American Patients
The White House
February 5, 2026HISTORIC LAUNCH TO LOWER DRUG PRICES FOR AMERICAN PATIENTS: Today, President Donald J. Trump announced the launch of TrumpRx.gov. Through the website, patients will be able to access large discounts on many of the most popular and highest-priced medicines in the country, paying prices in line with the lowest paid by other developed nations (known as the most-favored-nation, or MFN, price).
- Today’s launch features drugs made by the first five manufacturers to reach MFN pricing deals with the Trump Administration: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer.
- Additional drugs from other companies that have signed MFN pricing deals will be made available through TrumpRx.gov in the coming months.
- TrumpRx.gov provides patients with access to a world-class experience for accessing deep discounts on the medicines they need. Depending on the manufacturer of a given drug, patients with valid prescriptions will be able to access savings through user-friendly coupons that can be printed or downloaded onto their phones or through channels set up by the manufacturer and integrated into TrumpRx.gov.
DELIVERING LOWER COSTS ON THE MOST POPULAR DRUGS: As of today, patients purchasing directly through TrumpRx.gov will be able to see massive price reductions on 40 of the most popular and expensive branded medicines in the nation. Select examples include:
- Historic price reductions for Americans on the two drugs with the highest annual expenditures in the United States, which help adults struggling with diabetes, heart disease (Ozempic and Wegovy only), obesity, and other conditions.
- The monthly prices of Ozempic and injectable Wegovy will fall from $1,028 and $1,349, respectively, to an average price of $350 and as low as $199, depending on dosage strength.The monthly price of the Wegovy pill will fall from $1,349 to as low as $149, depending on dosage strength.
- The monthly price of Zepbound and will fall from $1,088 to an average price of $346 and as low as $299, depending on dosage strength.
- Massive savings on some of the most commonly used fertility medications in the country to help families grow. Many patients struggling with infertility pay for their medicines out-of-pocket, meaning they will stand to save more than $2,000 per cycle of fertility drugs, on average.
- Gonal-F, one of the most commonly-used fertility drugs, will see its price reduced to as low as $168 per pen, depending on dosage strength.
- The price of Cetrotide, another commonly used fertility medicine, will drop from $316 to $22.50.
- The price of Ovidrel will fall from $251 to $84.
- Discounts on numerous other high-cost drugs, including:
- Bevespi Aerosphere, an inhaler used to treat chronic obstructive pulmonary disease (COPD), will be discounted from $458 to $51.
- Airsupra, an inhaler used to treat asthma symptoms and attacks, will see a price drop from $504 to $201.
- Eucrisa, a topical ointment for atopic dermatitis, will be discounted from $792 to $158.
- Insulin Lispro will be available for as low as $25 per month.
- Duavee, a medication used to treat hot flashes and osteoporosis, will see its price cut from $202 to $30.
DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST: President Trump is delivering on promises to ensure American patients no longer pay high prices to subsidize low prices in the rest of the world, something the political establishment did not believe was possible.
- On May 12, 2025, President Trump signed an Executive Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” directing the Administration to take numerous actions to bring American drug prices in line with those paid by similar nations.
- On July 31, 2025, President Trump sent letters to leading pharmaceutical manufacturers outlining the steps they must take to bring down the prices of prescription drugs in the United States to match the lowest price offered in other developed nations.
- Since September 30, 2025, President Trump has announced 16 deals with major pharmaceutical manufacturers to bring prices in line with those paid in other developed nations, which will provide substantial price relief on numerous products taken by millions of Americans.
- On December 1, 2025, the Office of the United States Trade Representative, the Department of Commerce, and the Department of Health and Human Services announced an agreement with the United Kingdom (U.K.) that will increase the net price of new prescription drugs by 25% in the U.K., helping ensure that they pay their fair share for innovative medicines.
- On January 15, 2026, President Trump called on Congress to enact The Great Healthcare Plan, which would lower drug prices by codifying the savings from his Most-Favored-Nation pricing initiative, lower insurance premiums, hold insurance companies accountable, and maximize price transparency.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.














